Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence

  Рет қаралды 4,420

U.S. Food and Drug Administration

U.S. Food and Drug Administration

Күн бұрын

Пікірлер
Facility Readiness: GMPs, Quality Assessments, and Compliance Trends (15of16) GDF 2020
52:19
U.S. Food and Drug Administration
Рет қаралды 5 М.
Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD
28:12
U.S. Food and Drug Administration
Рет қаралды 10 М.
She made herself an ear of corn from his marmalade candies🌽🌽🌽
00:38
Valja & Maxim Family
Рет қаралды 18 МЛН
Une nouvelle voiture pour Noël 🥹
00:28
Nicocapone
Рет қаралды 9 МЛН
ICH M7(R1) - Chemistry and Manufacturing Control (CMC) Perspective on Hazard Assessment
20:33
U.S. Food and Drug Administration
Рет қаралды 7 М.
Mutagenic Impurities from a Drug Substance Perspective: Highlights from ICH M7 Q&A Draft Document
12:22
Post-approval Considerations for Changes to Manufacturing Process and Facilities - REdI 2020
28:11
CDER BIMO: Electronic Submission Requirements for New Drug and Biologic Licensing Applications
17:02
Evaluation of Metal Impurities in Drug Substances
15:42
U.S. Food and Drug Administration
Рет қаралды 2,8 М.
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session Two
1:42:25
U.S. Food and Drug Administration
Рет қаралды 1,6 М.
Establishing Impurity Acceptance Criteria as Part of Specs for DMFs Based on Clinical Relevance
13:26
Impurity Case Studies: Pharmacology/Toxicology (22of28) Generic Drugs Forum - Apr. 3-4, 2019
25:40
U.S. Food and Drug Administration
Рет қаралды 1,8 М.